

# Draft Genome Sequence of Methicillin-Resistant *Staphylococcus aureus* Strain SA16, Representative of an Endemic Clone from a Brazilian Hospital

Andrei Nicoli G. Dabul,<sup>a</sup> Veronica N. Kos,<sup>b,c</sup> Michael S. Gilmore,<sup>b,c</sup> Ilana L. B. C. Camargo<sup>a</sup>

Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brazil<sup>a</sup>; Departments of Ophthalmology and of Microbiology and Immunobiology, Harvard Microbial Sciences Initiative, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA<sup>b</sup>; The Broad Institute, Cambridge, Massachusetts, USA<sup>c</sup>

**Here we report the draft genome sequence of a bloodstream isolate of methicillin-resistant *Staphylococcus aureus* strain SA16. Strain SA16 is a sequence type 5 (ST5)-staphylococcal cassette chromosome *mec* type II (SCC*mec* II) clone and was the most prevalent isolate at a Brazilian hospital during the second half of 2009.**

Received 20 August 2013 Accepted 21 August 2013 Published 19 September 2013

**Citation** Dabul ANG, Kos VN, Gilmore MS, Camargo ILBC. 2013. Draft genome sequence of methicillin-resistant *Staphylococcus aureus* strain SA16, representative of an endemic clone from a Brazilian hospital. *Genome Announc.* 1(5):e00754-13. doi:10.1128/genomeA.00754-13.

**Copyright** © 2013 Dabul et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 3.0 Unported license](http://creativecommons.org/licenses/by/3.0/).

Address correspondence to Ilana L. B. C. Camargo, ilanacamargo@ifsc.usp.br.

Methicillin-resistant *Staphylococcus aureus* (MRSA) is an important nosocomial pathogen for which tracking is required to detect outbreaks.

An epidemiological study of MRSA isolated from infection sites in patients at a hospital in Belo Horizonte, Brazil, between July and December 2009 revealed the presence of an endemic sequence type 5 (ST5)-staphylococcal cassette chromosome *mec* type II (SCC*mec* II) clone (1) that is different from the ST239-SCC*mec* III strains typically encountered in Brazilian hospitals (2). The aim of this study was to characterize by whole-genome sequencing a MRSA isolate representative of this circulating clone. Strain SA16 was isolated from a patient's blood and identified as MRSA by use of the Vitek 2 (bioMérieux) system. Use of the Kirby-Bauer protocol showed this strain to be susceptible to vancomycin, amikacin, and gentamicin but resistant to oxacillin, ciprofloxacin, clindamycin, erythromycin, and penicillin. According to an Etest (bioMérieux), SA16 was also susceptible to daptomycin (MIC, 1 mg/liter), teicoplanin (MIC, 3 mg/liter), linezolid (MIC, 0.75 mg/liter), and tigecycline (MIC, 0.19 mg/liter) and had intermediate susceptibility to quinupristin-dalfopristin (MIC, 1.5 mg/liter).

Genomic DNA was extracted and purified and then submitted for Illumina HiSeq (Illumina) next-generation sequencing at the Tufts University DNA Core Facility (Boston, MA). Independently, genomic DNA was also subjected to 454 FLX (Roche) analysis at the University at Buffalo Next-Generation Sequencing and Expression Analysis Core (Buffalo, NY) to obtain coverage greater than 10-fold. The reads produced by both platforms were assembled into contigs by mapping them against a reference genome sequence (*S. aureus* N315) using CLC Genomics Workbench v 4.8.

Unmapped reads were then assembled into contigs by *de novo* assembly. The contigs of >200 bp ( $n = 74$ ) were annotated with the Prokaryotic Genome Annotation Pipeline v2.0 (NCBI) for deposition with GenBank. The draft genome sequence consists of

2,961,555 bp, with a GC content of 32.9%. Compared to the reference N315 genome sequence, 99% of the genome sequence was found to be shared.

Sequence analysis allowed classification of the clone as *agr* type II, *cap* type 5, and *spa* type t539. SA16 was found to harbor a typical virulence factor associated with CC5 strains (3–18). SA16 was also found to harbor *msrA*, *msrB*, *ermA*, and *ermC* genes, all related to streptogramin type B resistance (19). This may explain the intermediate level of resistance to quinupristin-dalfopristin. *ermC* is probably located on a plasmid, since it is present on a contig which does not match with the *S. aureus* N315 genome but aligns to various plasmids. SA16 also contains 2 intact phages,  $\phi$ MR25 and  $\phi$ N315.  $\phi$ N315 was also found in the N315 genome.

Sequencing of the *S. aureus* SA16 genome has generated the first draft genome sequence of a representative CC5 strain from Brazil, which provides a reference for further comparative genome analysis for studies of *S. aureus* isolates collected within this region. Also, this strain has been used by our group in the study of novel antimicrobial compounds and the structural study of *S. aureus* proteins.

**Nucleotide sequence accession numbers.** This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number [ASZO00000000](https://www.ncbi.nlm.nih.gov/nuccore/ASZO00000000). The version described in this paper is version ASZO01000000.

## ACKNOWLEDGMENTS

This work was supported by projects FAPESP 2010/02619-0, NIH/NIAID AI083214, and AI072360. A.N.G.D. was supported by grants from the Fundação de Amparo à Pesquisa do Estado de São Paulo (2010/11890-9).

## REFERENCES

1. Dabul AN, Camargo IL. 2013. Molecular characterization of methicillin-resistant *Staphylococcus aureus* resistant to tigecycline and daptomycin isolated in a hospital in Brazil. *Epidemiol. Infect.* 29:1–5.
2. Oliveira GA, Faria JB, Levy CE, Mamizuka EM. 2001. Characterization of the Brazilian endemic clone of methicillin-resistant *Staphylococcus au-*

- reus* (MRSA) from hospitals throughout Brazil. *Braz. J. Infect. Dis.* 5:163–170.
3. Que YA, François P, Haefliger JA, Entenza JM, Vaudaux P, Moreillon P. 2001. Reassessing the role of *Staphylococcus aureus* clumping factor and fibronectin-binding protein by expression in *Lactococcus lactis*. *Infect. Immun.* 69:6296–6302.
  4. Burke FM, McCormack N, Rindi S, Speziale P, Foster TJ. 2010. Fibronectin-binding protein B variation in *Staphylococcus aureus*. *BMC Microbiol.* 10:160. doi:10.1186/1471-2180-10-160.
  5. Lee LY, Miyamoto YJ, McIntyre BW, Höök M, McCrean KW, McDevitt D, Brown EL. 2002. The *Staphylococcus aureus* map protein is an immunomodulator that interferes with T cell-mediated responses. *J. Clin. Invest.* 110:1461–1471.
  6. Carneiro CR, Postol E, Nomizo R, Reis LF, Brentani RR. 2004. Identification of enolase as a laminin-binding protein on the surface of *Staphylococcus aureus*. *Microbes Infect.* 6:604–608.
  7. Downer R, Roche F, Park PW, Mecham RP, Foster TJ. 2002. The elastin-binding protein of *Staphylococcus aureus* (EbpS) is expressed at the cell surface as an integral membrane protein and not as a cell wall-associated protein. *J. Biol. Chem.* 277:243–250.
  8. Clarke SR, Harris LG, Richards RG, Foster SJ. 2002. Analysis of EbpA, a 1.1-megadalton cell wall-associated fibronectin-binding protein of *Staphylococcus aureus*. *Infect. Immun.* 70:6680–6687.
  9. Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM. 2008. *Staphylococcus aureus* clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. *J. Infect. Dis.* 198:125–133.
  10. Ricklin D, Ricklin-Lichtsteiner SK, Markiewski MM, Geisbrecht BV, Lambris JD. 2008. Cutting edge: members of the *Staphylococcus aureus* extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. *J. Immunol.* 181:7463–7467.
  11. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA. 2004. Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial anti-inflammatory agent. *J. Exp. Med.* 199:687–695.
  12. Makris G, Wright JD, Ingham E, Holland KT. 2004. The hyaluronate lyase of *Staphylococcus aureus*—a virulence factor? *Microbiology* 150:2005–2013.
  13. Wieckowska-Szakiel M, Sadowska B, Rózsalska B. 2007. Staphylokinase production by clinical *Staphylococcus aureus* strains. *Pol. J. Microbiol.* 56:97–102.
  14. Watanabe S, Ito T, Sasaki T, Li S, Uchiyama I, Kishii K, Kikuchi K, Skov RL, Hiramatsu K. 2009. Genetic diversity of staphylocoagulase genes (*coa*): insight into the evolution of variable chromosomal virulence factors in *Staphylococcus aureus*. *PLoS One* 4:e5714. doi:10.1371/journal.pone.0005714.
  15. Xue H, Lu H, Zhao X. 2011. Sequence diversities of serine-aspartate repeat genes among *Staphylococcus aureus* isolates from different hosts presumably by horizontal gene transfer. *PLoS One* 6:e20332. doi:10.1371/journal.pone.0020332.
  16. Dinges MM, Orwin PM, Schlievert PM. 2000. Exotoxins of *Staphylococcus aureus*. *Clin. Microbiol. Rev.* 13:16–34.
  17. Skaar EP, Schneewind O. 2004. Iron-regulated surface determinants (Isd) of *Staphylococcus aureus*: stealing iron from heme. *Microbes Infect.* 6:390–397.
  18. Johnson M, Cockayne A, Morrissey JA. 2008. Iron-regulated biofilm formation in *Staphylococcus aureus* Newman requires *ica* and the secreted protein Emp. *Infect. Immun.* 76:1756–1765.
  19. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. 1999. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. *Antimicrob. Agents Chemother.* 43:1062–1066.